Last reviewed · How we verify
Ro 205-2349
At a glance
| Generic name | Ro 205-2349 |
|---|---|
| Also known as | Edaglitazone |
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus (PHASE2)
- Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ro 205-2349 CI brief — competitive landscape report
- Ro 205-2349 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI